SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MGNX -- MacroGenics
An SI Board Since November 2013
Posts SubjectMarks Bans Symbol
188 21 0 MGNX
Emcee:  scaram(o)uche Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
113At SITC: finance.yahoo.comMiljenko Zuanic-11/10/2018
112Momo-therapy should have limited utility/efficacy (by target), while combinationMiljenko Zuanic-11/6/2018
111Anti-LAG3 data at #SITC18 (h/t AndyBiotech) First blush, looks pretty underwhetuck-11/6/2018
110They expanded trial to look for any biomarker association with FLZ activity in rMiljenko Zuanic-11/5/2018
109MGD006 underperforms other CD123 agents in AML at ASH, which explains the approatuck-11/5/2018
108edge.media-server.com Once again I am positively surprise by the CEO responds (Miljenko Zuanic-8/9/2018
107Note that Cohen was, and is not a registered lobbyist... newyorker.com <i&gnigel bates-5/10/2018
106Listen to the respond to ND MACE boundary end point analysts? TERRIBLE!!!!!!Miljenko Zuanic-5/9/2018
105OFF TOPIC Can anyone explain to me US policy (I may not be literal in English lMiljenko Zuanic-5/9/2018
104>> We may not be able to respond to @mentions and replies that...... Arscaram(o)uche-5/9/2018
103The agreement was for a term of one year, and paid Essential Consultants 100,000scaram(o)uche-5/9/2018
102It is hard to satisfy appetite of the Tramp's machinery. Is he blackmailing Miljenko Zuanic-5/9/2018
101Novartis apparently didn't pay Cohen enough.scaram(o)uche-5/9/2018
100Agreed!scaram(o)uche-5/8/2018
99One way or another, drug cost-control (as well as cost of development) need to bMiljenko Zuanic-5/8/2018
98>> stock sunk << We've been waiting for the drug cost-control mscaram(o)uche-5/8/2018
97And clarity did not improve after 1Q cc. INCY transferred IND for MGA012, but wMiljenko Zuanic-5/8/2018
96Secondary: Did they have "advance" knowledge about Ido-1 failure at INMiljenko Zuanic-4/12/2018
95Was secondary so necessary to price it at 21.25???? I do not like this at all!!Miljenko Zuanic-3/28/2018
94But, close to 15% decline, due to secondary, was not what I was looking for!Miljenko Zuanic-3/27/2018
93It was about time, finance.yahoo.com. Miljenko Zuanic-3/26/2018
92>> SUCKER << Bottom feeder, as in catfish. One step down is snailsscaram(o)uche-3/6/2018
91On a contrary note, when guy like Cilinski Lynn , (V.P.), addapt 10b5-1 plan ( 5Miljenko Zuanic-3/5/2018
904Q CC Incredible, it was "ONE MAN SHOW"! CEO, Scott Koenig, has capaciMiljenko Zuanic22/27/2018
894Q/2017 report: finance.yahoo.com <MGD019. This DART molecule is designed tMiljenko Zuanic-2/27/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News